J. Goldman & CO LP Novavax Inc Transaction History
J. Goldman & CO LP
- $3.21 Billion
- Q3 2024
Shares
1 transactions
Others Institutions Holding NVAX
# of Institutions
292Shares Held
93.4MCall Options Held
6.95MPut Options Held
9.4M-
Vanguard Group Inc Valley Forge, PA15.4MShares$131 Million0.0% of portfolio
-
Black Rock Inc. New York, NY11.8MShares$100 Million0.0% of portfolio
-
Shah Capital Management9.82MShares$83.1 Million40.63% of portfolio
-
State Street Corp Boston, MA7.69MShares$65.1 Million0.0% of portfolio
-
D. E. Shaw & Co., Inc. New York, NY5.94MShares$50.3 Million0.07% of portfolio
About NOVAVAX INC
- Ticker NVAX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 78,215,104
- Market Cap $662M
- Description
- Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; Nan...